Vallerie McLaughlin is a Cardiology physician affiliated with University of Michigan. OpenAlex indexes 914 publications with 34,262 citations (h-index 79); ClinicalTrials.gov lists 1 registered study matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Cardiovascular Disease profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingClinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
61 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
61 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
47.6%Endothelin Receptor Antagonist24%Opsumit90%Ambrisentan6%Letairis5%Part D<11 patientsLoop diuretic10.3%Furosemide63%Torsemide25%Bumetanide12%Part D≥87 patients+ 8 more classes in this area
Genitourinary & hormones
25.8%Phosphodiesterase 5 Inhibitor25.8%Sildenafil Citrate60%Tadalafil35%Revatio3%Adcirca2%Part D<11 patientsBlood & clotting
20.3%Prostacycline Vasodilator12.5%Tyvaso Dpi80%Veletri9%Orenitram Er6%Remodulin6%Part D<11 patientsProstacyclin Receptor Agonist4.6%Uptravi100%Part D≥26 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension
New England Journal of Medicine
2023 - Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension
Journal of the American College of Cardiology
2021 - Risk stratification and medical therapy of pulmonary arterial hypertension
European Respiratory Journal
2018
Similar KOLs
Other experts from the same institution or the same specialty.
Max Wicha, MD
University of Michigan
Dinesh Khanna, MD
University of Michigan
Eva Feldman, MD
University of Michigan
Matthias Kretzler, MD
University of Michigan
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Harlan Krumholz, MD
Yale School of Medicine
Scott Solomon, MD
Brigham and Women's Hospital
Eric Topol, MD
Scripps Research Institute (Scripps Research)
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”